Company Overview and News

 
Magmatic Resources confirms high-grade gold at Wellington North project in NSW

2018-08-20 proactiveinvestors.com.au
Magmatic Resources Ltd (ASX:MAG) has confirmed high-grade gold mineralisation in drilling at its Wellington North gold and copper project.
NCMGF NCM NCMGY EVN EVO 3993 CAHPF

 
Freightways, Sky TV lead NZ shares gain

2018-07-31 nzherald.co.nz
New Zealand shares gained, led higher by Freightways and Sky Network Television as the market remains quiet ahead of earnings season.
CEN ZNRGF KMD COENF SKT ZNZ GNE SYKWF SKC CEN SKKTY FGHRY KMD GEL KTHDY EBOSY FLT ZEL EBO COENY KWIPF EBOSF EVO GNE GTK EBO

 
MARKET WRAP: NZ shares rise: Serko up, Evolve down

2018-07-31 nbr.co.nz
New Zealand shares rose today as Serko and Evolve Education shares went in opposite directions in response to guidance updates.
CEN COENF MPP CEN MTPGF FGHRY EVO FLT COENY

13
Spark leads sharemarket higher

2018-05-28 nzherald.co.nz
New Zealand shares edged higher, led by Spark New Zealand and Arvida Group, while Scales Corp and Fisher & Paykel Healthcare weakened.
KTHDY FBU FCREY SPKKY NZTCY SPK NZTCF FRCEF FTRRF KMD FBU EVO KMD

 
Evolve to sell Porse after strategic review

2018-04-03 nbr.co.nz
Evolve Education Group has put its in-home childcare business Porse up for sale after a strategic review.
EVO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:EVO / EVOLVE EDUCATION GROUP LIMITED on message board site Silicon Investor.

Evolution Evolution Evolution Evoke Inc. - EVOK Evoke Inc. - EVOK Evoke Inc. - EVOK
Evolving Gold Corp. (EVG.V) Evolving Gold Corp. (EVG.V) Evolving Gold Corp. (EVG.V) Evolution - Moderated Evolution - Moderated Evolution - Moderated
EVOLUTION EVOLUTION EVOLUTION Winklevoss Bitcoin Trust ETF Winklevoss Bitcoin Trust ETF Winklevoss Bitcoin Trust ETF
MELu0027S PASSION OF CHRIST EVOKES SYNAGOGUEu0027S LOATHING MELu0027S PASSION OF CHRIST EVOKES SYNAGOGUEu0027S LOATHING MELu0027S PASSION OF CHRIST EVOKES SYNAGOGUEu0027S LOATHING EVFL - Evolution Fuels, Inc. EVFL - Evolution Fuels, Inc. EVFL - Evolution Fuels, Inc.
Evolving Systems, Inc. (EVOL) Evolving Systems, Inc. (EVOL) Evolving Systems, Inc. (EVOL) the revolution will not be televised the revolution will not be televised the revolution will not be televised